FreeTheAI

Verastem Oncology Names Michael P. Bailey as CEO Effective Jan. 1, 2027

BearishMedium impact
VSTM$7.45 −9.70%

Verastem, Inc. (NASDAQ:VSTM) announced that Michael P. Bailey will take over as President and Chief Executive Officer on January 1, 2027. He succeeds Daniel Paterson, who will retire from the top executive positions. Paterson will remain on the board of directors and serve as an advisor to the company. Following the announcement, Verastem shares dropped 9.70% to $7.45.

The planned leadership transition comes as the biopharmaceutical company moves from early product commercialization to scaling its development pipeline. Bailey has served on the board since May 2026, offering existing institutional familiarity to help manage execution risks. Verastem is focusing on commercial progress for its marketed drug AVMAPKI FAKZYNJA alongside pipeline advancement.

Investors will be watching upcoming clinical updates, including Phase 2 trial milestones for candidate VS-7375 and progress on confirmatory trials. Market participants will also monitor potential strategic revisions and financial guidance updates under Bailey's leadership leading into 2027.

Key points

  • Michael P. Bailey was named President and CEO of Verastem Oncology, effective January 1, 2027.
  • Outgoing CEO Daniel Paterson will retire from executive roles but remain a board member and advisor.
  • Bailey has served on Verastem's board of directors since May 2026.
  • Shares of Verastem fell 9.70% to $7.45 in trading following the announcement.
  • The transition occurs as the company scales commercial operations and Phase 2 trials for VS-7375.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

Who is the new CEO of Verastem Oncology?

Michael P. Bailey has been appointed as President and CEO of Verastem Oncology, taking office on January 1, 2027. He has served on the company board since May 2026.

When will Daniel Paterson step down as CEO of Verastem?

Daniel Paterson will step down as President and CEO on January 1, 2027. He will retain his position on the board of directors and serve as a corporate advisor.

What drugs does Verastem Oncology currently have?

Verastem Oncology currently has the drug AVMAPKI FAKZYNJA on the market and is advancing clinical candidate VS-7375 through Phase 2 trials.